167754-90-7

Upstream product

• 3810-12-6 (4-aminopyridin-3-yl)(phenyl)methanone 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 872890-50-1 N-{3-[(E)-[(1-benzylpiperidin-4-yl)imino](phenyl)methyl]pyridin-4-yl}-2,2,2-trichloroacetamide 
• 872890-51-2 3-[(E)-[(1-benzylpiperidin-4-yl)imino](phenyl)methyl]pyridin-4-amine 
• 872890-47-6 N-(3-benzoylpyridin-4-yl)-2,2,2-trichloroacetamide 
• 167754-48-5 3-[[(1-benzylpiperidin-4-yl)amino](phenyl)methyl]pyridin-4-amine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 167754-20-3 3-(piperidin-4-yl)-4-phenyl-2-oxo-1,2,3,4-tetrahydropyrido[4,3-d]pyrimidine 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationships of 3,4-dihydropyridopyrimidin-2(1H)-one derivatives as a novel class of sodium/calcium exchanger inhibitor

Design, synthesis, and structure-activity relationships for 3,4-dihydropyridopyrimidin-2(1H)-one derivatives, which are aza-3,4-dihydro- 2(1H)-quinazolinone derivatives, as the sodium/calcium (Na+/Ca 2+) exchanger inhibitors are disc

Quinazolinone derivatives possessing calcium uptake inhibiting activity

This invention is to provide quinazolinone derivatives, and their acid salts and quaternary ammonium salts, having an effect of preventing or treating diseases caused by calcium ion overload in cells, such as ischemic heart disease, ischemic cerebral disease and ischemic renal disease, and their usage. The quinazolinone derivatives are represented by the formula: STR1 typically, T represents an oxygen atom; Y represents a phenyl or cyclohexyl group; R1 represents a hydrogen or chlorine atom; R2 represents a hydrogen atom; ring W represents a benzene or pyridine ring; Z represents a group of the formula: STR2